Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;191(4):1647-1652.
doi: 10.1007/s11845-021-02761-6. Epub 2021 Sep 2.

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study

Satilmis Bilgin  1 , Ozge Kurtkulagi  1 , Tuba Taslamacioglu Duman  1 , Burcin Meryem Atak Tel  1 , Gizem Kahveci  1 , Murat Kiran  1 , Eray Erge  1 , Gulali Aktas  2
Affiliations

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study

Satilmis Bilgin et al. Ir J Med Sci. 2022 Aug.

Abstract

Background: Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, yielded significant beneficiaries in the treatment of type 2 diabetes mellitus (T2DM). It is particularly benefited the diabetic subjects with heart conditions.

Aims: We aimed to obtain a real-world data about the effects of empagliflozin add-on treatment on metabolic parameters, cardiovascular risk factors, and anthropometric measures in patients with T2DM.

Methods: Type 2 diabetic patients with established coronary heart disease whom empagliflozin added to their treatment were enrolled in the study. Anthropometric measures, clinical and laboratory data, were obtained before and at the 6th month of the empagliflozin treatment. All data before and at the 6th month were compared.

Results: Body weight (p < 0.001), body mass index (p < 0.001), waist (p < 0.001) and hip (p < 0.001) circumferences, systolic blood pressure (p = 0.006), heart rate (p = 0.01), LDL cholesterol (p = 0.01), fasting plasma glucose (p < 0.001), and HbA1c (p < 0.001) levels were significantly reduced on 6th month of empagliflozin treatment compared to the baseline values. Estimated GFR (p = 0.66), serum creatinine (p = 0.8), uric acid (p = 0.40), total cholesterol (p = 0.053), triglyceride (p = 0.057), and HDL (p = 0.09) levels were not significantly changed.

Conclusions: We suggest that empagliflozin treatment may improve anthropometric measures, metabolic parameters, and blood pressure and does not cause deterioration in kidney functions in type 2 diabetic patients with established coronary heart disease.

Keywords: Coronary heart disease; Empagliflozin; Fasting glucose; HbA1c; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Change in the study parameters between the initiation and the 6th month of the empagliflozin treatment
Fig. 2
Fig. 2
Change in the HbA1c levels between the initiation and the 6th month of the empagliflozin treatment
See this image and copyright information in PMC

References

    1. Chen MB, Wang H, Zheng QH, Xu HL, Cui WY. Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore) 2021;100(1):e24101. doi: 10.1097/md.0000000000024101. - DOI - PMC - PubMed
    1. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod MN. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF Trial. Circulation. 2021;143(17):1673–1686. doi: 10.1161/circulationaha.120.052503. - DOI - PubMed
    1. Li N, Zhou H. SGLT2 Inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy. Drug Des Devel Ther. 2020;14:4775–4788. doi: 10.2147/dddt.s269514. - DOI - PMC - PubMed
    1. von Lewinski D, Benedikt M, Tripolt N, Wallner M, Sourij H, Kolesnik E. Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction? Kardiol Pol. 2021;79(5):503–509. - PubMed
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. - DOI - PubMed

MeSH terms